Cyclerion Therapeutics Inc. (CYCN) is priced at $2.25 after the most recent trading session. At the very opening of the session, the stock price was $2.44 and reached a high price of $2.4484, prior to closing the session it reached the value of $2.50. The stock touched a low price of $2.25.
Recently in News on October 14, 2020, Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease. Study results do not support further internal development. You can read further details here
Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.
Cyclerion Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $8.96 on 09/18/20, with the lowest value was $2.08 for the same time period, recorded on 03/12/20.
Cyclerion Therapeutics Inc. (CYCN) full year performance was -83.25%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Cyclerion Therapeutics Inc. shares are logging -84.77% during the 52-week period from high price, and 33.14% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.69 and $14.77.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1115798 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Cyclerion Therapeutics Inc. (CYCN) recorded performance in the market was -17.28%, having the revenues showcasing -44.44% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 78.08M, as it employees total of 94 workers.
Analysts verdict on Cyclerion Therapeutics Inc. (CYCN)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.43, with a change in the price was noted -2.98. In a similar fashion, Cyclerion Therapeutics Inc. posted a movement of -56.98% for the period of last 100 days, recording 435,490 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CYCN is recording 0.05 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Cyclerion Therapeutics Inc. (CYCN): Technical Analysis
Raw Stochastic average of Cyclerion Therapeutics Inc. in the period of last 50 days is set at 0.00%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 0.00%. In the last 20 days, the company’s Stochastic %K was 1.03% and its Stochastic %D was recorded 1.30%.
Let’s take a glance in the erstwhile performances of Cyclerion Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -17.28%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -41.86%, alongside a downfall of -83.25% for the period of the last 12 months. The shares increased approximately by -13.46% in the 7-day charts and went up by -67.34% in the period of the last 30 days. Common stock shares were lifted by -44.44% during last recorded quarter.